10-Q: Senti Biosciences Reports Q1 2025 Financial Results, Cites Going Concern Uncertainty

Sentiment:

Quarterly Report 6 May 2025 4:48 PM

Senti Biosciences reports a net loss of $14.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Capital raiseThe company states that additional funds will be necessary to maintain current operations and to continue research and development activities.The company entered into a sales agreement with Leerink Partners for an at-the-market offering program of up to $17.5 million of its common stock.

Worse than expectedThe company reported a larger net loss compared to the same period last year.The company expresses substantial doubt about its ability to continue as a going concern.

Summary

Senti Biosciences, a clinical-stage biotechnology company, filed its Form 10-Q for the quarter ended March 31, 2025.
The company is developing next-generation cell and gene therapies using its gene circuit platform.
Senti reported a net loss of $14.1 million for the three months ended March 31, 2025, compared to a net loss of $12.1 million for the same period in 2024.
Research and development expenses were $9.3 million, and general and administrative expenses were $7.1 million.
As of March 31, 2025, Senti had cash and cash equivalents of $33.8 million and an accumulated deficit of $311.2 million.
The company states that substantial doubt exists about its ability to continue as a going concern for at least one year from the issuance date of the financial statements.
Senti is actively pursuing additional financing to maintain operations and continue research and development activities.
The company is relying on third-party manufacturers, including GeneFab, for the production of its product candidates.
A Phase 1 clinical trial of SENTI-202 for blood cancers is ongoing, and a clinical trial for SENTI-301A/SN301A for solid tumors, conducted by Celest Therapeutics, has ceased enrollment due to dose-limiting toxicities.
Senti terminated its A&R Purchase Agreement with Chardan Capital Markets on March 17, 2025.
On March 20, 2025, Senti entered into a sales agreement with Leerink Partners for an at-the-market offering program of up to $17.5 million of its common stock.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are ongoing clinical trials and efforts to secure funding, the company's financial losses and going concern warning weigh heavily on the sentiment.

Positives

Senti Biosciences is actively pursuing additional financing to maintain operations and continue research and development activities.
A Phase 1 clinical trial of SENTI-202 for blood cancers is ongoing.
Senti entered into a sales agreement with Leerink Partners for an at-the-market offering program of up to $17.5 million of its common stock on March 20, 2025.

Negatives

Senti Biosciences reported a net loss of $14.1 million for Q1 2025.
Senti expresses substantial doubt about its ability to continue as a going concern.
Celest Therapeutics stopped dosing in its SN301A clinical trial due to dose limiting toxicities.
Senti terminated its A&R Purchase Agreement with Chardan Capital Markets on March 17, 2025.

Risks

The company's ability to continue as a going concern is dependent on raising additional capital and developing profitable operations.
Clinical trials may not demonstrate the safety and efficacy necessary for regulatory approval.
The company relies on third-party manufacturers, and any failure by these parties could disrupt the supply of product candidates.
The company faces competition from other companies developing therapies for the same diseases.
The company is exposed to product liability risks and may not be able to obtain sufficient insurance coverage.
The company identified a material weakness in its internal control over financial reporting.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future and anticipates that expenses and operating losses will increase substantially.

Industry Context

The company operates in the competitive biotechnology industry, focusing on cell and gene therapies. The industry is characterized by high R&D costs, lengthy regulatory processes, and competition from established pharmaceutical companies and other biotechnology firms.

Comparison to Industry Standards

It is difficult to compare Senti Biosciences directly to industry standards due to its unique gene circuit platform technology.
However, similar clinical-stage biotechnology companies often face challenges in securing funding and demonstrating clinical efficacy.
Companies like CRISPR Therapeutics and Beam Therapeutics, which are also developing novel gene editing therapies, serve as comparables in terms of technology and market focus.
These companies also experience volatility in their stock prices and face regulatory hurdles.
Senti's cash position and burn rate will be closely watched by investors, as these metrics are critical for assessing the company's ability to fund its operations and advance its pipeline.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Interim Chief Financial Officer	Yvonne Li	Timothy Lu, M.D., Ph.D.	2025-01-31	Expiration of Consulting Agreement
Chief Financial Officer	Timothy Lu, M.D., Ph.D.	Jay Cross	2025-03-03	Appointment of new CFO

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	Feng Hsiung was appointed to the Board of Directors, increasing the number of members from six to seven.	2025-03-07	Potentially strengthens board oversight and expertise.
Audit Committee	Feng Hsiung was appointed as a member of the Audit Committee.	2025-03-07	Potentially strengthens audit committee oversight.
Equity Incentive Plan	The Amended and Restated 2022 Equity Incentive Plan was approved, increasing the number of shares available for issuance.	2025-03-06	Provides more flexibility for equity-based compensation.

Legal Proceedings

The Company is subject to claims and assessments from time to time in the ordinary course of business but does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Companys financial position, results of operations, or cash flows.

Related Party Transactions

The company has significant related party transactions with GeneFab, including prepaid expenses, sublease income, and research and development expenses.
NEA, Celadon Partners, and Bayer Healthcare LLC are considered related parties due to their significant shareholdings and board representation.

Stakeholder Impact

Shareholders face the risk of dilution from potential future equity offerings.
Employees may be affected by potential cost-cutting measures or restructuring.
Customers (potential patients) may experience delays in the availability of new therapies.
Suppliers and creditors may be impacted by the company's financial challenges.

Next Steps

Continue to advance the SENTI-202 clinical trial.
Seek regulatory approval for product candidates.
Expand operational, financial, and management systems.
Continue to develop, maintain, enforce and defend intellectual property portfolio.
Raise additional capital.

Key Dates

Date	Description
2021-05-25	Dynamics Special Purpose Corp. (DYNS) Initial Public Offering (IPO)
2022-06-08	Transactions contemplated by the terms of the Agreement were completed on June 8, 2022 (the Closing), in conjunction with which DYNS changed its name to Senti Biosciences, Inc.
2023-08-07	The Company entered into a framework agreement (the GeneFab Framework Agreement) with GeneFab and Valere Bio, Inc.
2024-08-03	The Company executed an agreement with California Institute for Regenerative Medicine (CIRM) for a total grant award of $8.0 million (CIRM Grant)
2024-12-02	The Company entered into a securities purchase agreement with certain investors in which the Company agreed to sell, in a private placement (the Offering), (i) up to 21,157 shares of Series A redeemable convertible preferred stock, par value $0.0001 per share, for an aggregate offering price of $47.6 million and (ii) accompanying warrants to purchase up to 31,735,500 shares of common stock, par value $0.0001 per share.
2024-12-09	The Company closed the initial tranche of the Offering, in which the Company issued 16,713 shares of Series A redeemable convertible preferred stock and Warrants to purchase 25,069,500 shares of common stock for $35.2 million, net of issuance costs of $2.4 million.
2024-12-10	The Company, GeneFab and Valere Bio, Inc. entered into an amendment to the GeneFab Framework Agreement, pursuant to which the GeneFab Note Receivable was waived by the parties.
2024-12-31	The Company closed the second tranche of the Offering, in which the Company issued 4,444 shares of Series A redeemable convertible preferred stock and Warrants to purchase 6,666,000 shares of common stock for $9.9 million, net of issuance costs of $0.1 million.
2025-01-31	Yvonne Li, the Consulting Agreement by and between the Company and Yvonne Li, the Companys Interim Chief Financial Officer, expired in accordance with its terms.
2025-02-05	The Company and Ms. Li entered into a new consulting agreement pursuant to which Ms. Li will serve as a consultant to the Company and will cooperate with the Companys executive management team and other functional teams on an orderly transition of her responsibilities until March 31, 2025.
2025-02-23	Jay Cross was appointed as our Chief Financial Officer, effective as of March 3, 2025.
2025-03-06	At our special meeting of stockholders, our stockholders approved the issuance of common stock in accordance with Nasdaq Listing Rule 5635 upon (i) conversion of Series A redeemable convertible preferred stock and (ii) the exercise of warrants to purchase shares of common stock.
2025-03-07	Our Board of Directors approved the appointment of Feng Hsiung, pursuant to the terms of a letter agreement dated as of December 2, 2024, by and between us and Celadon Partners.
2025-03-10	We sent notices to our stockholders relating to the conversion of 21,157 shares of Series A redeemable convertible preferred stock into 21,157,000 shares of common stock, effective as of March 10, 2025.
2025-03-17	The Company provided notice to Chardan that it was terminating the A&R Purchase Agreement.
2025-03-20	We entered into the 2025 ATM Agreement with Leerink Partners with respect to an at-the-market offering program under which we may offer and sell, from time to time at our sole discretion, up to a maximum aggregate offering price of $17.5 million of our common stock through Leerink Partners as our sales agent.
2025-04-28	We announced certain corporate updates including preliminary data from a Phase 1 clinical trial of SENTI-202

Keywords

Senti Biosciences, financial results, going concern, clinical trials, gene circuit platform, SENTI-202, SENTI-301A, biotechnology, Leerink Partners, Chardan Capital Markets, Celest Therapeutics

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.